ODOMZO\u00ae is the commercial brand name of Sonidegib Phosphate Capsules, an orally active Hedgehog pathway inhibitor developed by Sun Pharmaceutical Industries. It exerts anti-tumor activity by binding to and inhibiting the Smoothened (SMO) receptor, thereby blocking aberrant activation of the Hedgehog signaling pathway and suppressing the proliferation of basal cell carcinoma cells.<\/p>\n\n\n\n
Main Indications<\/strong> Common Side Effects<\/strong> Approval Status in China<\/strong> Buy ODOMZO (Sonidegib Phosphate Capsules)\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" ODOMZO\u00ae is the commercial brand name of Sonidegib Phosphate Capsules, an orally active Hedgehog pathway inhibitor developed by Sun Pharmaceutical Industries. It exerts anti-tumor activity by binding to and inhibiting the Smoothened (SMO) receptor, thereby blocking aberrant activation of the Hedgehog signaling pathway and suppressing the proliferation of basal cell carcinoma cells. Main IndicationsTreatment of […]<\/p>\n","protected":false},"author":4,"featured_media":3317,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101],"tags":[],"class_list":["post-3316","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-news"],"blocksy_meta":[],"yoast_head":"\n
Treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy.<\/p>\n\n\n\n
Common adverse reactions: Muscle spasms, alopecia, dysgeusia, fatigue, nausea, diarrhea, weight loss, decreased appetite, myalgia, and headache.
Laboratory abnormalities: Elevated serum creatine kinase (CK), increased lipase, increased amylase, and elevated transaminases.
Severe but manageable risks: Musculoskeletal toxicity (including severe muscle spasms and elevated CK), teratogenicity (embryo-fetal death or severe birth defects), and hepatotoxicity.<\/p>\n\n\n\n
ODOMZO\u00ae (Sonidegib Phosphate Capsules, 200mg) was officially approved for marketing in China in 2021. It is currently a prescription drug included in China\u2019s Category B medical insurance.<\/p>\n\n\n\n